Garry Dolton

Title: Garry Dolton: Innovator in Cancer Treatment

Introduction

Garry Dolton is a prominent inventor based in Cardiff, South Glamorgan, GB. He has made significant contributions to the field of cancer treatment through his innovative research and development of new therapeutic methods. With a total of four patents to his name, Dolton is recognized for his dedication to advancing medical science.

Latest Patents

Garry Dolton's latest patents include groundbreaking work on cancer-specific T-cell receptors. This patent relates to a new anti-cancer peptide, along with a vector encoding the peptide, and various pharmaceutical compositions or vaccines that utilize this peptide for cancer treatment. Additionally, he has developed a method for treating cancer using these innovative agents. Another notable patent involves a gamma delta T-cell receptor and its ligand, which includes a T-cell expressing the receptor, a clone, and a vector encoding the receptor. This patent also covers the use of these components in cancer treatment, showcasing Dolton's commitment to improving therapeutic options for patients.

Career Highlights

Garry Dolton is affiliated with University College Cardiff Consultants Limited, where he continues to push the boundaries of cancer research. His work has garnered attention in the scientific community, and he is recognized for his contributions to immunotherapy and cancer treatment strategies.

Collaborations

Dolton collaborates with Andrew Kelvin Sewell, a fellow researcher in the field. Their partnership has led to advancements in understanding T-cell receptors and their applications in cancer therapy.

Conclusion

Garry Dolton's innovative work in cancer treatment exemplifies the impact of dedicated research and collaboration in the medical field. His patents reflect a commitment to developing effective therapies that can significantly improve patient outcomes.